Last updated: February 23, 2026
What is NDC 00023-6150?
NDC 00023-6150 refers to Tamoxifen citrate 20 mg. This drug is primarily used in the treatment of hormone receptor-positive breast cancer and as a preventive therapy in high-risk populations.
Current Market Landscape
Industry Size and Key Players
The global breast cancer treatment market was valued at approximately USD 13 billion in 2022. Tamoxifen remains a leading therapy, accounting for an estimated 15% market share of hormone-related breast cancer drugs.
Major manufacturers include:
- AstraZeneca (branded product: Nolvadex)
- Teva Pharmaceuticals
- Mylan (now part of Viatris)
- Sun Pharmaceutical Industries
Market Penetration and Usage Trends
Tamoxifen's widespread use for both treatment and prevention sustains high demand. Usage rates are especially high in the US, Europe, and parts of Asia. The drug's generic availability since the early 2000s has increased access, leading to growing prescription volume.
Pricing Landscape
Branded vs. Generic Pricing
| Product Type |
Price per 20 mg tablet (USD) |
Market Share |
Notes |
| Branded (Nolvadex) |
$5.50 – $8.00 |
~50% |
Historically higher; decreased as generics entered |
| Generic (various) |
$0.30 – $0.80 |
~50% |
Widely available; price competition suppresses cost |
Regulatory Environment Impact
The patent for the branded Nolvadex expired around 2003, facilitating generic competition. Recent regulatory approvals for biosimilar and alternative formulations have increased affordability.
Price Projections (2023–2028)
Assumptions
- Steady demand driven by breast cancer incidence
- Continued generic penetration
- No major patent litigation or regulatory barriers
- No significant price inflation, with a typical decrease of 2–3% annually for generics
Forecast Summary
| Year |
Average Price per 20 mg Tablet (USD) |
Expected Market Conditions |
| 2023 |
$0.40 – $0.80 |
Stable with high generic competitiveness |
| 2024 |
$0.40 – $0.78 |
Slight reduction driven by price pressure |
| 2025 |
$0.39 – $0.75 |
Increased market share for low-cost generics |
| 2026 |
$0.38 – $0.73 |
Regulatory approvals facilitate more options |
| 2027 |
$0.37 – $0.70 |
Price stabilization as market matures |
| 2028 |
$0.36 – $0.68 |
Marginal decline continues |
The average wholesale price for the 20 mg tablet will remain within the current range but trend toward the lower end of the spectrum. Price reductions align with increased market penetration of generics and cost-driven policy pressures.
Market Drivers and Risks
Drivers
- Rising breast cancer prevalence: Estimated at 12% lifetime risk among women globally
- Growing adoption of preventive therapy in high-risk groups
- Continued generic entry reducing costs
Risks
- Regulatory hurdles for newer formulations
- Competition from biosimilars or alternative therapies
- Changes in healthcare policy affecting reimbursement
Key Takeaways
- NDC 00023-6150 (Tamoxifen citrate 20 mg) commands a competitive generic market.
- Prices have decreased from branded levels of approximately $5.50–$8.00 to current average generic prices of about $0.30–$0.80.
- Market growth depends on breast cancer incidence rates, preventive therapy adoption, and the pace of generic penetration.
- Price projections show a gradual decline consistent with historical trends and market dynamics.
- Regulatory and policy environment influences the pace of price changes and market entry.
FAQs
Q1: How does the current market for Tamoxifen compare globally?
The US and Europe have high prescription volumes driven by breast cancer prevalence, with generics making up a significant share of the market, especially in countries with healthcare systems capable of negotiating lower drug prices.
Q2: What factors could accelerate price decreases for NDC 00023-6150?
Introduction of biosimilars, further patent expirations, and increased competition from alternative treatments could drive prices lower.
Q3: Are there upcoming regulatory changes that could impact prices?
Potentially, regulatory approvals for biosimilars or new formulations could alter the competitive landscape, influencing pricing strategies.
Q4: How does the demand for Tamoxifen influence its price stability?
Stable or increasing demand driven by breast cancer incidence ensures ongoing revenue, although high generic competition tends to suppress price growth.
Q5: Which markets represent the largest future opportunities?
Emerging markets in Asia and Latin America present significant growth opportunities due to expanding healthcare access and rising cancer incidence rates.
Sources:
- MarketWatch. (2023). Breast cancer therapeutics market size.
- IQVIA. (2022). Global Prescription Drug Market Data.
- AstraZeneca. (2023). Nolvadex product information.
- FDA. (2022). Approved biosimilars and generic drugs.
- WHO. (2022). Global cancer statistics.
